全文获取类型
收费全文 | 85795篇 |
免费 | 6702篇 |
国内免费 | 3703篇 |
专业分类
耳鼻咽喉 | 812篇 |
儿科学 | 3335篇 |
妇产科学 | 2231篇 |
基础医学 | 10665篇 |
口腔科学 | 3656篇 |
临床医学 | 5934篇 |
内科学 | 9761篇 |
皮肤病学 | 966篇 |
神经病学 | 4222篇 |
特种医学 | 3287篇 |
外国民族医学 | 30篇 |
外科学 | 16650篇 |
综合类 | 12403篇 |
现状与发展 | 14篇 |
预防医学 | 3778篇 |
眼科学 | 2373篇 |
药学 | 6129篇 |
22篇 | |
中国医学 | 2400篇 |
肿瘤学 | 7532篇 |
出版年
2024年 | 97篇 |
2023年 | 764篇 |
2022年 | 1436篇 |
2021年 | 2345篇 |
2020年 | 1999篇 |
2019年 | 1979篇 |
2018年 | 2192篇 |
2017年 | 2368篇 |
2016年 | 2647篇 |
2015年 | 2909篇 |
2014年 | 4936篇 |
2013年 | 5800篇 |
2012年 | 4764篇 |
2011年 | 5603篇 |
2010年 | 4776篇 |
2009年 | 4841篇 |
2008年 | 4942篇 |
2007年 | 5165篇 |
2006年 | 4727篇 |
2005年 | 4469篇 |
2004年 | 3713篇 |
2003年 | 3165篇 |
2002年 | 2542篇 |
2001年 | 2241篇 |
2000年 | 2066篇 |
1999年 | 1670篇 |
1998年 | 1401篇 |
1997年 | 1275篇 |
1996年 | 1130篇 |
1995年 | 985篇 |
1994年 | 883篇 |
1993年 | 766篇 |
1992年 | 669篇 |
1991年 | 571篇 |
1990年 | 519篇 |
1989年 | 425篇 |
1988年 | 350篇 |
1987年 | 311篇 |
1986年 | 320篇 |
1985年 | 383篇 |
1984年 | 305篇 |
1983年 | 194篇 |
1982年 | 289篇 |
1981年 | 216篇 |
1980年 | 179篇 |
1979年 | 167篇 |
1978年 | 141篇 |
1977年 | 126篇 |
1976年 | 98篇 |
1973年 | 77篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
KGF在乳腺癌的表达与临床意义 总被引:1,自引:0,他引:1
目的:探讨KGF蛋白在人乳腺癌的表达与意义,与临床病理因素及生物学指标的相关性。方法: 采用免疫组化方法检测KGF在63例乳腺癌组织中的表达,并与正常乳腺组织对照。结果:63例乳腺癌组织中34例肿瘤细胞表达KGF(54.0%),正常乳腺上皮细胞未表达(P<0.01),在乳腺癌间质细胞和正常乳腺组织间质细胞表达率分别为34.9%和16.7%(P>0.05)。其在肿瘤细胞中的表达与低分化相关,与ER、PR呈负相关,与Ki-67呈正相关,与Ki-67的协同表达与淋巴结转移正相关。结论: KGF在乳腺癌肿瘤细胞的表达可能促进乳腺癌的发生发展,并且与低分化、预后不良有关。 相似文献
92.
三维骨建模在全膝关节置换术中韧带平衡的作用 总被引:3,自引:3,他引:0
吴昊 《中国修复重建外科杂志》2006,20(6):607-610
目的探讨以三维骨建模为基础、无需影像的计算机辅助系统在人工全膝关节置换术(totalknee arthroplasty,TKA)中韧带平衡的作用。方法2002年11月~2003年6月,采用后稳定型人工全膝关节,在Ceravision无需影像资料的三维骨建模系统导航监控下,辅助完成TKA21例。男5例,女16例,年龄64~79岁,平均72.4岁。其中2例既往行胫骨近端截骨术,1例行股骨远端截骨术。14例膝内翻,7例膝外翻。术前下肢全长X线正位片测量,内翻13°~外翻13°,平均2.36°;膝关节X线正位片测量,应力下内翻平均8.47°(内翻2°~内翻20°),应力下外翻平均3.63°(内翻7°~外翻12°)。结果术中导航系统测量,额面内翻12°~外翻10°,平均3.33°,与术前比较差异有统计学意义(P<0.05);额面应力下内翻平均6.47°(内翻0°~内翻24°),应力下外翻平均4.32°(内翻8°~外翻15°),与术前比较差异有统计学意义(P<0.05)。术毕导航系统测得膝内外翻平均0.175°(内翻2°~外翻3°),而术后下肢全长X线正位片测量平均0.3°(内翻3.5°~外翻1.5°),二者差异无统计学意义(P>0.05)。术后3个月关节活动度为105~130°,平均115°,膝关节额面松弛度0.2~0.5cm,平均0.27cm。人工膝关节胫、股骨假体取得满意的对位置入和韧带平衡,无关节失稳和髌骨脱位等并发症发生。结论以三维骨建模为基础、无需影像的Ceravision系统,具有三维立体定位、优化截骨,并通过旋转对位和韧带松解获得伸屈膝关节等距间隙与韧带平衡稳定的作用,近期临床疗效满意,可在TKA中常规使用。 相似文献
93.
Haruhito Adam Uchida Yoshio Nakamura Masanobu Kaihara Hisanao Norii Yoshihisa Hanayama Hitoshi Sugiyama Yohei Maeshima Yasushi Yamasaki Hirofumi Makino 《Nephrology, dialysis, transplantation》2006,21(12):3475-3480
BACKGROUND: Decreased plasma adiponectin is associated with impaired endothelial function and, thereby, increased risk for cardiovascular events. Glucocorticoid (GC) affects vascular endothelial cells either favourably or harmfully depending upon the dosages and duration. We examined the effect of GC pulse therapy on vascular endothelial function. METHODS: Fourteen young patients with IgA nephropathy were evaluated for flow-mediated vasodilation (FMD), plasma levels of adiponectin both in high molecular weight (HMW adiponectin) form and in single molecular form (total adiponectin), hepatocyte growth factor (HGF), asymmetric dimethylarginine (ADMA), and high-sensitive C-reactive protein, before and after a course of GC pulse therapy. RESULTS: GC pulse therapy significantly decreased FMD (from 7.2 +/- 2.6 to 5.7 +/- 2.5%, P < 0.01). Meanwhile, plasma adiponectin levels were significantly augmented (total adiponectin: from 10.2 +/- 4.0 to 12.1 +/- 6.3 microg/ml, P < 0.05; HMW: from 6.5 +/- 3.2 to 7.7 +/- 3.3 microg/ml, P < 0.05). In parallel, elevated concentrations of serum HGF (from 0.28 +/- 0.12 to 0.63 +/- 0.38 ng/ml, P < 0.01) and plasma ADMA (from 0.45 +/- 0.07 to 0.53 +/- 0.04 nmol/ml, P < 0.05) were observed. CONCLUSIONS: GC pulse therapy impaired endothelial function while increasing plasma adiponectin levels, which may in turn restore the endothelial function in patients with IgA nephropathy. 相似文献
94.
分子靶向药物bevacizumab是针对血管内皮生长因子(VEGF)的重组人源化单克隆抗体,在多种恶性肿瘤的治疗中显示了临床效果。现就bevacizumab的作用机制及其在乳腺癌治疗中的临床研究进展作一综述。 相似文献
95.
幽门螺杆菌相关性胃溃疡胃癌组织中VEGF的表达及意义 总被引:1,自引:0,他引:1
目的:研究幽门螺杆菌(HP)感染与胃溃疡、胃癌组织中血管内皮生长因子(VEGF)表达的关系及意义.方法:应用免疫组化SABC法检测36例胃溃疡、52例胃癌组织中HP及VEGF的表达.结果:胃溃疡组织中HP阳性组的VEGF表达(53.6%)明显高于HP阴性组(12.5%),两组间比较有显著性差异(P<0.05);胃癌组织中HP阳性组的VEGF表达(84%)明显高于HP阴性组(40.7%),两组间比较差异显著(P<0.05).结论:HP感染可增加VEGF的表达,HP阳性组胃溃疡组织中VEGF表达可能与胃溃疡发病的时段有关. 相似文献
96.
表皮生长因子对牛眼小梁细胞c—fos基因表达的诱导 总被引:4,自引:0,他引:4
目的研究表皮生长因子(epidermalgrowthfactor,EGF)对小梁细胞的作用。方法应用分子杂交技术研究EGF对体外培养的牛眼小梁细胞c-fos基因表达的诱导和3H胸腺核苷酸(3H-thymidineincorparation,3H-TdR)掺入法观察细胞DNA的合成。结果小梁细胞的3H-TdR掺入率随着EGF浓度不同而变化,浓度为20~150ng/ml时,细胞掺入率随浓度增加升高(P<0.01)。与对照组相比,EGF刺激停止生长的小梁细胞0.5小时后,c-fos基因开始表达,1小时后达高峰,至2小时后消失。不同浓度EGF刺激小梁细胞1小时后,c-fos基因表达呈浓度依赖性。结论实验结果表明EGF刺激小梁细胞增殖或进入生长状态,可能与c-fos基因产物的信号传递作用有关。 相似文献
97.
Hirotaka Koizuml Mikita Morita Shinya Mikaml Eiichi Shibayama Toshiyuki Uchikoshi 《Pathology international》1998,48(2):93-101
The Trk family of tyrosine protein kinase receptors plays a significant role in the development and maintenance of neural tissues. It has been recently shown that Trk receptors are also expressed by a wide range of normal non-neuronal tissues in humans in a cell type-specific manner. In the present study, the expression patterns of TrkA in 337 non-neuronal invasive carcinomas of 15 different human tissues were investigated immunohistochemically. Overall, 133 (39%), 101 (30%) and 103 (31%) tumors exhibited strong, moderate and no TrkA Immunoreactivity, respectively. Esophageal and thyroid carcinomas expressed high levels of TrkA, whereas the levels in gastric and colon cancers were low. TrkA expression was detected not only in carcinomas originating from TrkA-positive normal counterpart tissues, Including the esophagus, breast, lung and uterus, but also in those from TrkA-negative tissues/cells of the thyroid, liver and ovary. Immunostaining for nerve growth factor-β, the specific ligand for TrkA, in esophageal and breast carcinomas demonstrated its immunoreactivity in stromal fibroblasts and some TrkA-expressing tumor cells. These results suggest that paracrine/autocrine regulation via stromal/tumoral NGF-tumoral TrkA interaction may be involved In the growth of certain non-neuronal carcinomas. 相似文献
98.
Basic fibroblast growth factor mRNA, bFGF peptide and FGF receptor in epiretinal membranes of intraocular proliferative disorders (PVR and PDR) 总被引:3,自引:0,他引:3
Arno Hueber Peter Wiedemann Peter Esser Klaus Heimann 《International ophthalmology》1997,20(6):345-350
Basic fibroblast growth factor (bFGF) has been shown to be involved in epiretinal membrane formation in proliferative vitreoretinal disorders. However, up to now, little knowledge exists, as to the actual cellular source of this potent mitogen.We examined 20 epiretinal membranes from patients with proliferative diabetic retinopathy (PDR) (n = 12) and proliferative vitreoretinopathy (PVR) (n = 8) for the presence of bFGF peptide, fibroblast growth factor receptor-1 (FGFR-1) and bFGF messenger ribonucleic acid (mRNA).Using a specific antibody, we detected bFGF peptide in most (8/10) examined PDR membranes and in all (8/8) PVR membranes. Moreover, we found positive staining for the corresponding receptor.Local production of bFGF in epiretinal membranes was confirmed by nonisotopic in situ hybridisation for bFGF mRNA in some (4/7) examined PDR membranes and some (3/4) examined PVR membranes. All membranes which contained bFGF mRNA were also positive for bFGF peptide.In conclusion, bFGF is produced and stored in epiretinal membranes. Together with the corresponding receptor, bFGF may play a role in the auto- and paracrine control of the proliferative processes at the vitroretinal interface.Abbreviations aFGF
acidic fibroblast growth factor
- bFGF
basic fibroblast growth factor
- FGFR-1
fibroblast growth factor receptor-1
- mRNA
messenger ribonucleic acid 相似文献
99.
后路治疗胸腰椎爆裂骨折 总被引:3,自引:0,他引:3
目的:探讨后路环椎管减压,椎弓根钉系统复位固定并植骨治疗胸腰椎爆裂骨折的疗效。方法:1996-2001年,环椎环椎管减压,结合具有钉杆角的椎弓根钉系统复位固定,并横突及小关节突间植骨或椎间植骨治疗128例病人,从伤椎椎体前后缘高度恢复,Cobb角矫正度及神经功能恢复情况评价疗效。结果:128例病人脊髓神经损害无加重,神经功能有不同程度恢复;伤椎高度恢复理想,Cobb角明显减少,植骨融合成功108例(占84.4%),术后部分病例出现伤椎复位度丢失现象。结论:后路环椎管减压内固定治疗胸腰椎骨折效果好,应重视植骨融合以获得良好稳定性。 相似文献
100.
R. P. Heaney T. M. Zizic I. Fogelman W. P. Olszynski P. Geusens C. Kasibhatla N. Alsayed G. Isaia M. W. Davie C. H. Chesnut III 《Osteoporosis international》2002,13(6):501-505
Risedronate treatment reduces the risk of vertebral fracture in women with existing vertebral fractures, but its efficacy
in prevention of the first vertebral fracture in women with osteoporosis but without vertebral fractures has not been determined.
We examined the risk of first vertebral fracture in postmenopausal women who were enrolled in four placebo-controlled clinical
trials of risedronate and who had low lumbar spine bone mineral density (BMD) (mean T-score =–3.3) and no vertebral fractures at baseline. Subjects received risedronate 5 mg (n= 328) or placebo (n= 312) daily for up to 3 years; all subjects were given calcium (1000 mg daily), as well as vitamin D supplementation (up
to 500 IU daily) if baseline serum 25-hydroxyvitamin D levels were low. The incidence of first vertebral fracture was 9.4%
in the women treated with placebo and 2.6% in those treated with risedronate 5 mg (risk reduction of 75%, 95% confidence interval
37% to 90%; P= 0.002). The number of patients who would need to be treated to prevent one new vertebral fracture is 15. When subjects were
stratified by age, similar significant reductions were observed in patients with a mean age of 64 years (risk reduction of
70%, 95% CI 8% to 90%; P= 0.030) and in those with a mean age of 76 years (risk reduction of 80%, 95% CI 7% to 96%; P= 0.024). Risedronate treatment therefore significantly reduces the risk of first vertebral fracture in postmenopausal women
with osteoporosis, with a similar magnitude of effect early and late after the menopause.
Received: 12 September 2001 / Accepted: 11 December 2001 相似文献